SEHK:9969Biotechs
InnoCare Pharma (SEHK:9969) Wins IND Approval, Is The Upside Already Priced In?
The recent approval of InnoCare Pharma (SEHK:9969)’s IND application for ICP-B381 by China’s drug regulator gives investors a new clinical asset to watch in the company’s antibody drug conjugate pipeline.
That IND approval landed after a strong run in InnoCare Pharma’s share price, with a 90-day share price return of 42.66% and a year-to-date share price gain of 22.80%, even though the 1-year total shareholder return declined 12.59% and the 5-year total shareholder return fell 25.67%.
Scan...